Back to discover
Drug

Regadenoson

Approved · EMA
Emerging researchLate-stage development
RxNorm640062ChEMBLCHEMBL317052UNII7AXV542LZ4
1
Research papers
3
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

Clinical trial2026-07-07Results expected Q1 2027 · ClinicalTrials.gov

An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Pediatric Patients

Clinical trial2026-05-06Results expected Q4 2026 · ClinicalTrials.gov

Defining Mechanisms for Cardiac Allograft Dysfunction to Improve Allograft Longevity and Survival in Heart-Transplant Patients

Clinical trial2026-05-01Results expected Q1 2027 · ClinicalTrials.gov

MyocardiAl CT Perfusion and Coronary Flow: a CompreHensive Cardiac CT Myocardial Perfusion Imaging (MPI)/Fractional Flow Reserve (FFR) and PET-CT MPI Evaluation (The MATCH Investigation)

Clinical trial2026-01-06Results posted · ClinicalTrials.gov

Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult Patients

Clinical trial2025-03-20Results posted · ClinicalTrials.gov

Regadenoson Real Time Perfusion Imaging Trial

Clinical trial2024-12-27Results posted · ClinicalTrials.gov

A Phase 2, Open-Label, Randomized, Cross-Over Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging by Multidetector Computed Tomography (MDCT) and Single Photon Emission Computed Tomography (SPECT)

Clinical trial2024-12-04Results posted · ClinicalTrials.gov

A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson

Clinical trial2024-12-03Results posted · ClinicalTrials.gov

Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging

Clinical trial2024-10-02Results posted · ClinicalTrials.gov

A Randomized, Blinded, Multi-site, Pilot Study to Evaluate Adenosine 2A Receptor Agonist (REGADENOSON) in the Rehabilitation of Marginal Donor Lungs.

Clinical trial2024-07-31Completed · ClinicalTrials.gov

A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.

Research2012-04-07Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Approval: Rapiscan (EMA)

Regulatory2010-09-06EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Regadenoson
RxNorm CUI
640062
ChEMBL ID
CHEMBL317052
UNII
7AXV542LZ4
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2010-09-06
Latest approval
2010-09-06
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2010-09-06Approval
Approval: Rapiscan (EMA)
Indication: This medicinal product is for diagnostic use only. Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion… Show full indication

This medicinal product is for diagnostic use only. Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

48 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
48
registered trials across all phases
LATEST COMPLETION 2024
3
Active studies
3
Recruiting
28
Late-stage (III+)
34
Completed
11
Discontinued
PHASE DISTRIBUTIONn = 48
Early Phase 15Phase 16Phase 1 / 22Phase 27Phase 34Phase 413Phase N / A11

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Defining Mechanisms for Cardiac Allograft Dysfunction to Improve Allograft Longevity and Survival in Heart-Transplant Patients

RecruitingPH IVPaul Kimn=3762027

Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging

CompletedPH IVM.D. Anderson Cancer Centern=1612024

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

CompletedPH IVMarvin W. Kronenberg, M.D.n=552020

Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve

TerminatedPH IVDuke Universityn=312019

Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease

Unknown statusPH IVDipan Shahn=502018

Recent completions

Trials that read out recently, adding to the completed evidence base.

MyocardiAl CT Perfusion and Coronary Flow: a CompreHensive Cardiac CT Myocardial Perfusion Imaging (MPI)/Fractional Flow Reserve (FFR) and PET-CT MPI Evaluation (The MATCH Investigation)

CompletedN/AEmory Universityn=202024

A Randomized, Blinded, Multi-site, Pilot Study to Evaluate Adenosine 2A Receptor Agonist (REGADENOSON) in the Rehabilitation of Marginal Donor Lungs.

CompletedPH IUniversity of Maryland, Baltimoren=472024

Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging

CompletedPH IVM.D. Anderson Cancer Centern=1612024

Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult Patients

CompletedPH I/IIUniversity of Maryland, Baltimoren=52023

Heart Rate Response to Regadenoson and Sudden Cardiac Death

CompletedN/AUniversity of Alabama at Birminghamn=902022

Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF

CompletedPH IVMarvin W. Kronenberg, M.D.n=552020

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2012 · 51 cites
Recent papers

A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2012 · 51 cites
Journals, researchers & institutions
Top journals
  • Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology1
Leading researchers
  • Behm S1
  • Bukofzer S1
  • Feaheny K1
  • McNutt BE1
  • Prenner BM1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.